ZAI LAB(09688) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

09688 ZAI LAB

Watchlist

27.150
-0.400-1.45%

Closing Auction Session Mar 26 16:07 CST

29.76BMarket Cap-14.92P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Health Check: How Prudently Does Zai Lab (NASDAQ:ZLAB) Use Debt?
Simply Wall StMar 25 09:20 ET
BofA Securities Maintains Zai Lab(ZLAB.US) With Hold Rating, Maintains Target Price $36.1
Moomoo NewsMar 25 02:31 ET · Ratings
Zai Lab's Stable Growth and Competitive Challenges Justify Hold Rating
TipRanksMar 24 06:55 ET · Ratings
Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
MT NewswiresMar 21 10:38 ET
Express News | Trump: Xi Will Be Coming “in the Not Too (Not 'to') Distant Future”
ReutersMar 17 20:54 ET
Zai Lab to Announce 2024 Annual Results With HK Listing Compliance
TipRanksMar 17 09:18 ET

Comments

Teddy123

Mar 13 09:58

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

$Zai Lab (ZLAB.US)$
China Accepts TIVDAK Application: 45% Lower Death Risk in Cervical Cancer Trial

Sean Parker

Jan 23 16:01

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

$Zai Lab (ZLAB.US)$
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...